scholarly journals Spontaneous Pneumothorax in COVID-19 Patients Treated with High-Flow Nasal Cannula outside the ICU: A Case Series

2021 ◽  
Vol 18 (4) ◽  
pp. 2191
Author(s):  
Magdalena Nalewajska ◽  
Wiktoria Feret ◽  
Łukasz Wojczyński ◽  
Wojciech Witkiewicz ◽  
Magda Wiśniewska ◽  
...  
Keyword(s):  
Spontaneous Pneumothorax ◽  
Previous History ◽  
Case Series ◽  
High Flow ◽  
Nasal Cannula ◽  
High Flow Nasal Cannula ◽  
Positive Effects ◽  
Non Invasive ◽  
Global Pandemic ◽  
History Of

The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic and a burden to global health at the turn of 2019 and 2020. No targeted treatment for COVID-19 infection has been identified so far, thus supportive treatment, invasive and non-invasive oxygen support, and corticosteroids remain a common therapy. High-flow nasal cannula (HFNC), a non-invasive oxygen support method, has become a prominent treatment option for respiratory failure during the SARS-CoV-2 pandemic. HFNC reduces the anatomic dead space and increases positive end-expiratory pressure (PEEP), allowing higher concentrations and higher flow of oxygen. Some studies suggest positive effects of HFNC on mortality and avoidance of intubation. Spontaneous pneumothorax has been observed in patients suffering from SARS-CoV-2 pneumonia. Although the viral infection itself contributes to its development, higher PEEP generated by both HFNC and mechanical ventilation is another risk factor for increased alveoli damage and air-leak. Herein, we present three cases of patients with no previous history of lung diseases who were diagnosed with COVID-19 viral pneumonia. All of them were supported with HFNC, and all of them presented spontaneous pneumothorax.

scholarly journals An air-locking port and high-flow nasal cannula in non-intubated uniportal video-assisted thoracic surgery for pneumothorax with pulmonary dysfunction: a case report

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Hiroya Yamagishi ◽  
Yusuke Wakatsuki ◽  
Toshihiko Tada ◽  
Tadashi Matsukura
Keyword(s):  
Thoracic Surgery ◽  
Flow Rate ◽  
Spontaneous Pneumothorax ◽  
High Flow ◽  
Nasal Cannula ◽  
High Flow Rate ◽  
High Flow Nasal Cannula ◽  
Video Assisted Thoracic Surgery ◽  
Secondary Spontaneous Pneumothorax ◽  
Video Assisted

Abstract Background Non-intubated video-assisted thoracic surgery is a therapeutic option for intractable secondary spontaneous pneumothorax in patients who are poor candidates for surgery with endotracheal intubation under general anesthesia. However, intraoperative respiratory management in this surgery is often challenging because of hypoxia caused by surgical pneumothorax. Case presentation A 75-year-old man with idiopathic pulmonary fibrosis who had been on home oxygen therapy underwent non-intubated uniportal video-assisted thoracic surgery for intractable spontaneous pneumothorax. During the operation, oxygen was administered using a high-flow nasal cannula at a high flow rate. An air-locking port for single-incision surgery was used to minimize the inflow of air into the pleural cavity. The intrapleural air was continuously suctioned through the chest tube. The air-leak point was easily identified and closed using ligation. Oxygenation was satisfactory throughout the operation. Conclusions Non-intubated uniportal video-assisted thoracic surgery for secondary spontaneous pneumothorax with an air-locking port, continuous pleural suction, and high-flow nasal cannula may achieve satisfactory intraoperative oxygenation in patients with respiratory dysfunction. The intrapleural space can be feasible for surgical manipulation without surgical pneumothorax in non-intubated video-assisted thoracic surgery even when supplied with oxygen at a high flow rate using a high-flow nasal cannula.

scholarly journals High flow nasal cannula oxygen therapy in adults with COVID-19 respiratory failure. A case report

2020 ◽  
Vol 90 (2) ◽  
Author(s):  
Vasileios Karamouzos ◽  
Fotini Fligou ◽  
Charalambos Gogos ◽  
Dimitrios Velissaris
Keyword(s):  
Respiratory Failure ◽  
Oxygen Therapy ◽  
Virus Disease ◽  
High Flow ◽  
Nasal Cannula ◽  
High Flow Nasal Cannula ◽  
Non Invasive ◽  
Corona Virus ◽  
Non Invasive Ventilation ◽  
Hypoxic Respiratory Failure

The novel corona virus (SARS-CoV-2) continuous to spread around the globe causing high mortality, tremendous stress on healthcare systems and an unprecedented disruption of everyday life with unpredictable socioeconomic ramifications. The diseaseis typically affecting the respiratory system and some patients will develop refractory hypoxemic respiratory insufficiency requiring mechanical ventilation. The role of non-invasive ventilation (NIV), high flow nasal cannula (HFNC) or continuous positive airway pressure devices (C-PAP) in the treatment of the 2019 corona virus disease (COVID-19) is not yet clear. We hereby report a case of a 44-year-old COVID-19 positive male patient suffering from hypoxic respiratory failure that was successfully treated with high flow nasal cannula oxygen therapy in a negative pressure intensive care room. Although specific criteria for the use of high flow nasal canula devices COVID-19 are not available at this time, clinicians could use this non-invasive modality as analternative method of respiratory support in selected patients presenting with respiratory failure.

scholarly journals High-flow nasal cannula oxygen therapy to treat patients with hypoxemic acute respiratory failure consequent to SARS-CoV-2 infection

Thorax ◽  
2020 ◽  
Vol 75 (11) ◽  
pp. 998-1000 ◽  
Author(s):  
Andrea Vianello ◽  
Giovanna Arcaro ◽  
Beatrice Molena ◽  
Cristian Turato ◽  
Andi Sukthi ◽  
...  
Keyword(s):  
Respiratory Failure ◽  
Acute Respiratory Failure ◽  
High Flow ◽  
Nasal Cannula ◽  
High Flow Nasal Cannula ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Non Invasive ◽  
Non Invasive Ventilation ◽  
Hypoxemic Acute Respiratory Failure

This observational study aims to assess the outcome and safety of O2-therapy by high-flow nasal cannula (HFNC) in 28 consecutive patients with severe hypoxemic acute respiratory failure (hARF) consequent to SARS-CoV-2 infection, unresponsive to conventional O2-therapy. Nineteen patients had a positive response. Nine patients required escalation of treatment to non-invasive ventilation (five subsequently intubated). None of the staff had a positive swab testing during the study period and the following 14 days. Severity of hypoxemia and C reactive protein level were correlated with HFNC failure. These data suggest HFNC to be a safe treatment for less severe patients with SARS-CoV-2 hARF and efficacy will need to be assessed as part of a clinical trial.

scholarly journals Use of high-flow nasal cannula in obese patients receiving colonoscopy under intravenous propofol sedation: A case series

2018 ◽  
Vol 23 ◽  
pp. 118-121 ◽  
Author(s):  
Chi Chan Lee ◽  
Osman Perez ◽  
Faryal I. Farooqi ◽  
Trupti Akella ◽  
Sameer Shaharyar ◽  
...  
Keyword(s):  
Case Series ◽  
High Flow ◽  
Nasal Cannula ◽  
Obese Patients ◽  
High Flow Nasal Cannula ◽  
Propofol Sedation

A case series of paediatric high flow nasal cannula therapy

2013 ◽  
Vol 26 (4) ◽  
pp. 189-192 ◽  
Author(s):  
Sara Mayfield ◽  
Jacqueline Jauncey-Cooke ◽  
Fiona Bogossian
Keyword(s):  
Case Series ◽  
High Flow ◽  
Nasal Cannula ◽  
High Flow Nasal Cannula
Sign in / Sign up

Export Citation Format

Share Document